Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Roche's Ipatasertib?
Ipatasertib is a small molecule commercialized by Roche, with a leading Phase III program in Human Epidermal Growth Factor Receptor...
Ipatasertib by Genentech USA for Metastatic Breast Cancer: Likelihood of Approval
Ipatasertib is under clinical development by Genentech USA and currently in Phase III for Metastatic Breast Cancer. According to GlobalData,...
Ipatasertib by Genentech USA for Solid Tumor: Likelihood of Approval
Ipatasertib is under clinical development by Genentech USA and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Ipatasertib by Genentech USA for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Ipatasertib is under clinical development by Genentech USA and currently in Phase III for Human Epidermal Growth Factor Receptor 2...
Ipatasertib by Genentech USA for Hypopharyngeal Cancer: Likelihood of Approval
Ipatasertib is under clinical development by Genentech USA and currently in Phase I for Hypopharyngeal Cancer. According to GlobalData, Phase...
Ipatasertib by Genentech USA for Laryngeal Cancer: Likelihood of Approval
Ipatasertib is under clinical development by Genentech USA and currently in Phase I for Laryngeal Cancer. According to GlobalData, Phase...
Ipatasertib by Genentech USA for Oropharyngeal Cancer: Likelihood of Approval
Ipatasertib is under clinical development by Genentech USA and currently in Phase I for Oropharyngeal Cancer. According to GlobalData, Phase...
Ipatasertib by Genentech USA for Paranasal Sinus And Nasal Cavity Cancer: Likelihood of Approval
Ipatasertib is under clinical development by Genentech USA and currently in Phase I for Paranasal Sinus And Nasal Cavity Cancer....
Ipatasertib by Genentech USA for Oral Cavity (Mouth) Cancer: Likelihood of Approval
Ipatasertib is under clinical development by Genentech USA and currently in Phase I for Oral Cavity (Mouth) Cancer. According to...
Ipatasertib by Genentech USA for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Ipatasertib is under clinical development by Genentech USA and currently in Phase I for Head And Neck Squamous Cell Carcinoma...